| Name | Title | Contact Details |
|---|
Microbot Medical was founded with the vision of pioneering Micro Invasive Surgery, transforming one of the biggest trends in healthcare - Minimally Invasive Surgery (estimated to be close to $20B by 2015); the company will provide transformational micro invasive technologies with the accuracy of robots and automated instruments to assist physicians in targeting the disease site with exquisite precision. Microbot will solve one of the largest unmet needs in the medical field, where morbidity as a result of surgery is more frequently due to trauma involved in gaining access to the area to perform the intended procedure rather than from the procedure itself. Through its unique platforms, Microbot will reach multiple surgical spaces, capitalizing on the fact that minimally invasive techniques have been applied to most of the surgical specialties. Microbot`s ViRob platform is an Autonomous Advancing Micro Robot (AAMR), less then 1mm in diameter, which has the ability to advance (forward/backward) within cavities/lumens (such as the typical human body`s veins and arteries). The TipCat platform is a self-propelled, flexible, see & treats endoscope/catheter. It is comprised of a series of interconnected balloons that provide forward and backward motion while allowing for a working channel to be available during the procedure. In developing its platforms, the company is focusing on multi-disciplinary platform of products.
MedWrap Corp. is a Buffalo, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
bill tobin is a Port Chester, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
JenaValve Technology, Inc., based in Irvine, California and Munich, Germany develops, manufactures and markets transcatheter aortic valve implantation (TAVI) systems to treat patients suffering from aortic valve disease. The Company’s transapical TAVI system is CE marked and currently marketed in Europe and other markets worldwide and its new transfemoral TAVI system is currently undergoing clinical evaluation in Europe with a view toward achieving CE Mark in 2015. JenaValve is backed by world-class U.S., European and Asian investors, including Atlas Venture, Edmond de Rothschild Investment Partners, GIMV, NeoMed Management, Legend Capital, VI Partners, Sunstone Capital, Omega Funds, Biovest and Valiance Advisors.